Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | TFPI | P10646 | 1/20 | 0.48 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.48 |
| ▸ | CBX7 | O95931 | 1/20 | 0.48 |
| ▸ | CBX8 | Q9HC52 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433466 | 0.93 | NPBWR1 (0.51) | OPRM1OPRD1OPRK1TFPINPBWR1 | |
| SCHEMBL31433305 | 0.92 | OPRM1 (0.47) | OPRM1OPRD1OPRK1CTSB | |
| SCHEMBL31433365 | 0.90 | TFPI (0.54) | TFPIOPRL1NPBWR1 | |
| SCHEMBL31433357 | 0.90 | TFPI (0.54) | OPRM1OPRD1OPRK1TFPIOPRL1 | |
| SCHEMBL31433281 | 0.89 | NPY5R (0.51) | NPBWR1 | |
| SCHEMBL31516071 | 0.86 | TFPI (0.54) | OPRM1OPRD1OPRK1TFPICDYL2 | |
| SCHEMBL31433308 | 0.85 | IL23R (0.50) | OPRM1OPRD1OPRK1 | |
| SCHEMBL31256987 | 0.85 | OPRD1 (0.61) | OPRM1OPRD1OPRK1CDYL2CBX7 | |
| SCHEMBL31236826 | 0.84 | OPRK1 (0.62) | OPRM1OPRD1OPRK1CTSB | |
| SCHEMBL29568516 | 0.84 | OPRK1 (0.62) | OPRM1OPRD1OPRK1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | OPRM1 2906/4885OPRD1 3640/4885OPRK1 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.